Stifel analyst Jonathan Block raised the firm’s price target on Envista (NVST) to $27 from $25 and keeps a Buy rating on the shares as part of the firm’s 2026 overview note for the dental, diabetes, and aesthetics sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST: